Literature DB >> 21070923

Depression as a potential modulator of Beta-adrenergic-associated leukocyte mobilization in heart failure patients.

Laura S Redwine1, Petra H Wirtz, Suzi Hong, Jos A Bosch, Jos Bosch, Michael G Ziegler, Barry Greenberg, Paul J Mills.   

Abstract

OBJECTIVES: the aim of this study was to determine whether depressive symptoms are related to alterations in the sensitivity of peripheral blood mononuclear cells to β-adrenergic agonists in patients with heart failure (HF) by measuring in vitro chemotaxis (CTX) to isoproterenol at rest and after acute exercise in patients with HF and controls.
BACKGROUND: clinical outcomes are worse for patients with HF presenting with symptoms of depression. Sympathetically modulated immune dysregulation associated with depression may be one mechanism leading to worse prognosis.
METHODS: seventy-seven patients with HF and 44 controls (mean age 56.4 ± 1.3 years) completed the Beck Depression Inventory and a 15-min mild-graded exercise task on a stationary bicycle. Exercise intensity was kept relative to fitness levels for all participants by gradually increasing resistance to reach a Borg scale subjective rating of 12 to 13, "somewhat hard." Plasma norepinephrine and epinephrine levels were measured before and after exercise. Chemotaxis to isoproterenol was determined by measuring in vitro peripheral blood mononuclear cell migration through a modified Boyden chamber.
RESULTS: In patients with HF, depressive symptom severity was associated with greater CTX after exercise (p = 0.001). Higher resting norepinephrine in patients with HF was also associated with increased CTX to exercise (p = 0.03).
CONCLUSIONS: patients with HF with higher depressive symptoms and norepinephrine exhibited increased peripheral blood mononuclear cell CTX to isoproterenol to mild exercise, suggesting greater β-adrenergic sensitivity. Increased immune migration in patients with HF who have elevated depressive symptoms could be associated with cardiac remodeling and HF disease progression. 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21070923      PMCID: PMC2999627          DOI: 10.1016/j.jacc.2010.04.064

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  35 in total

1.  Missing data techniques for structural equation modeling.

Authors:  Paul D Allison
Journal:  J Abnorm Psychol       Date:  2003-11

2.  Neurohormonal and inflammatory hyper-responsiveness to acute mental stress in depression.

Authors:  Ali A Weinstein; Patricia A Deuster; Jennifer L Francis; Robert W Bonsall; Russell P Tracy; Willem J Kop
Journal:  Biol Psychol       Date:  2010-01-29       Impact factor: 3.251

3.  Psychological risk factors may moderate pharmacological treatment effects among ischemic heart disease patients. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators.

Authors:  T Rutledge; W Linden; R F Davies
Journal:  Psychosom Med       Date:  1999 Nov-Dec       Impact factor: 4.312

Review 4.  Autonomic innervation and regulation of the immune system (1987-2007).

Authors:  Dwight M Nance; Virginia M Sanders
Journal:  Brain Behav Immun       Date:  2007-04-27       Impact factor: 7.217

5.  Perceived exertion as an indicator of somatic stress.

Authors:  G Borg
Journal:  Scand J Rehabil Med       Date:  1970

6.  Attenuation of T-lymphocyte demargination and adhesion molecule expression in response to moderate exercise in physically fit individuals.

Authors:  Suzi Hong; Todd A Johnson; Noha H Farag; Harold J Guy; Scott C Matthews; Michael G Ziegler; Paul J Mills
Journal:  J Appl Physiol (1985)       Date:  2004-10-22

7.  Peptide T blocks GP120/CCR5 chemokine receptor-mediated chemotaxis.

Authors:  L S Redwine; C B Pert; J D Rone; R Nixon; M Vance; B Sandler; M D Lumpkin; D J Dieter; M R Ruff
Journal:  Clin Immunol       Date:  1999-11       Impact factor: 3.969

8.  Impaired T-cell dependent humoral response and its relationship with T lymphocyte sensitivity to stress hormones in a chronic mild stress model of depression.

Authors:  D M Silberman; V Ayelli-Edgar; M Zorrilla-Zubilete; L M Zieher; A M Genaro
Journal:  Brain Behav Immun       Date:  2004-01       Impact factor: 7.217

9.  A potential shift from adaptive immune activity to nonspecific inflammatory activation associated with higher depression symptoms in chronic heart failure patients.

Authors:  Laura S Redwine; Petra H Wirtz; Suzi Hong; Ines Pandzic; Stephanie Cammarata; Joseph Tafur; Steven M Carter; Barry Greenberg; Paul J Mills
Journal:  J Card Fail       Date:  2009-03-14       Impact factor: 5.712

10.  Effects of acute mental stress and exercise on inflammatory markers in patients with coronary artery disease and healthy controls.

Authors:  Willem J Kop; Neil J Weissman; Jianhui Zhu; Robert W Bonsall; Margaret Doyle; Micah R Stretch; Sami B Glaes; David S Krantz; John S Gottdiener; Russell P Tracy
Journal:  Am J Cardiol       Date:  2008-02-21       Impact factor: 2.778

View more
  3 in total

1.  Leukocyte ß-adrenergic receptor sensitivity and depression severity in patients with heart failure.

Authors:  Laura S Redwine; Suzi Hong; Thomas Rutledge; Bailey Wentworth; Meredith Pung; Michael G Ziegler; Alan Maisel; Barry Greenberg; Paul J Mills
Journal:  Psychosom Med       Date:  2014 Nov-Dec       Impact factor: 4.312

2.  Beta-adrenergic receptor mediated inflammation control by monocytes is associated with blood pressure and risk factors for cardiovascular disease.

Authors:  Suzi Hong; Stoyan Dimitrov; Tiefu Cheng; Laura Redwine; Christopher Pruitt; Paul J Mills; Michael G Ziegler; J Michael Green; Farah Shaikh; Kathleen Wilson
Journal:  Brain Behav Immun       Date:  2015-08-20       Impact factor: 7.217

3.  Digestive Enzyme Activity and Protein Degradation in Plasma of Heart Failure Patients.

Authors:  Vasiliki Courelli; Alla Ahmad; Majid Ghassemian; Chris Pruitt; Paul J Mills; Geert W Schmid-Schönbein
Journal:  Cell Mol Bioeng       Date:  2021-08-13       Impact factor: 2.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.